Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Abstract: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: Recombinant expression vectors are provided comprising a 3?UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.

Abstract: Recombinant expression vectors are provided comprising a 3? UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.

Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.

Abstract: The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression.

Abstract: The invention provides for nucleic acid molecules encoding a CAB-2 protein and variants thereof. The invention also provides constructs, transformed eukaryotic cells, and methods of producing CAB-2 protein and variants thereof.

Abstract: Recombinant expression vectors are provided comprising a 3? UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.

Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.